Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
200%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph not_applicable
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Enrolling by invitation1
Recruiting1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)

Trials by Status

enrolling_by_invitation125%
recruiting125%
completed125%
terminated125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
enrolling_by_invitationnot_applicable

Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)

NCT06693856
completedphase_1

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

NCT02348216
terminatedphase_2

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

NCT01465334

Clinical Trials (4)

Showing 4 of 4 trials
NCT04862221Phase 2

TReatment for ImmUne Mediated PathopHysiology

Recruiting
NCT06693856Not Applicable

Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)

Enrolling By Invitation
NCT02348216Phase 1

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed
NCT01465334Phase 2

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4